Serina has developed a proprietary clinical candidate called SER-214, a POZ polymer conjugate of the potent dopamine agonist known as rotigotine. When SER-214 is delivered subcutaneously, it provides continuous dopaminergic stimulation and steady-state levels of plasma rotigotine that cannot be achieved by any other approach.
Serina Therapeutics’ Investigational New Drug (IND) application for SER-214 was approved by the FDA for enrollment of Parkinson’s disease patients and we began enrolling patients in January 2016. The study completed enrollment in July 2017. Based upon market research in over 150 practicing neurologists who are experts in movement disorders, we believe SER-214 will be used primarily in de novo onset patients as well as transitioning patients who are experiencing “wearing off” and early dyskinesia.
The POZ Platform
Targeting moiety is an antibody (single chain, antibody fragment, targeting polypeptide)
Programmable loading of the polymer allows for very high drug antibody ratios (DAR) – for example, by multiple site attachment to resident –SH in the antibody
May prove to be particularly important for low-density targets
POZ polymer ADCs may have improved therapeutic index and enhanced half-life = greater engagement of target cancers